Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SOLU MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SOLU MEDROL.
FLUDROCORTISONE ACETATE vs SOLU-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.
0.1 mg orally once daily, range 0.05-0.2 mg/day
IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%.
Category D/X
Category C
Corticosteroid
Corticosteroid